Global Dyskinesia Pipeline Review 2016 - Research and Markets

Research and Markets has announced the addition of the "Dyskinesia - Pipeline Review, H2 2016" report to their offering.

Dyskinesia pipeline therapeutics constitutes close to 45 molecules. Out of which approximately 42 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 10, 6, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Dyskinesia - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Key Topics Covered:

1. Introduction
2. Dyskinesia Overview
3. Therapeutics Development
4. Pipeline Products for Dyskinesia - Overview
5. Pipeline Products for Dyskinesia - Comparative Analysis
6. Dyskinesia - Therapeutics under Development by Companies
7. Dyskinesia - Therapeutics under Investigation by Universities/Institutes
8. Dyskinesia Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Dyskinesia - Products under Development by Companies
13. Dyskinesia - Products under Investigation by Universities/Institutes
14. Dyskinesia - Companies Involved in Therapeutics Development

• Adamas Pharmaceuticals, Inc.
• Addex Therapeutics Ltd
• Advicenne
• Astraea Therapeutics, LLC
• Bionomics Limited
• Catalyst Biosciences, Inc.
• Catalyst Pharmaceuticals, Inc.
• Clevexel Pharma SAS
• Contera Pharma ApS
• EpiVax, Inc.
• Heptares Therapeutics Limited
• Hua Medicine (Shanghai) Ltd.
• Integrative Research Laboratories Sweden AB
• Ipsen S.A.
• Merz Pharma GmbH & Co. KgaA
• MitoDys Therapeutics Limited
• Neurim Pharmaceuticals Ltd
• Neurocrine Biosciences, Inc.
• Neurolixis Inc.
• Osmotica Pharmaceutical Corp.
• Otsuka Holdings Co., Ltd.
• Phenomenome Discoveries, Inc.
• Revance Therapeutics, Inc.
• Sage Therapeutics, Inc.
• SciFluor Life Sciences, LLC
• SOM Innovation Biotech SL
• Synchroneuron Inc.
• Teva Pharmaceutical Industries Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/5q4rjz/dyskinesia

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006442/en/